Please ensure Javascript is enabled for purposes of website accessibility



We have the knowledge and expertise to handle the most demanding and complex transactions and provide expert, efficient and cost effective services to all our clients. Our commercial understanding and experience of working with leading financial institutions, professional advisers and regulatory bodies enable us to add real value to our clients’ businesses.

View all services


Our experts provide independent guidance spanning advice and training to implementation and evaluation across sustainable investing, regulatory compliance and tech. Our tailored advice meets clients' specific needs, delivering flexible solutions and support.

View all Consulting


Our sector approach relies on smart collaboration between our business divisions, our service lines and our jurisdictions. These sector-based teams have a deep understanding of related businesses and industry dynamics. The specific combination of our highly informed experts helps our clients see around corners.

View all sectors


Ogier provides practical advice on BVI, Cayman Islands, Guernsey, Irish, Jersey and Luxembourg law through our global network of offices across the Asian, Caribbean and European timezones. Ogier is the only firm to advise on this unique combination of laws.

News and insights

Keep up to date with industry insights, analysis and reviews. Find out about the work of our expert teams and subscribe to receive our newsletters straight to your inbox.

Fresh thinking, sharper opinion.

About us

We get straight to the point, managing complexity to get to the essentials. Our global network of offices covers every time zone. 

No Content Set

Ogier advises biotech healthcare company MiRXES Pte Ltd on US$77 million Series C financing


01 October 2021

Hong Kong

Save as PDF

Ogier's corporate team in Hong Kong has acted as Cayman counsel to MiRXES Pte Ltd (MiRXES) for its US$77 million Series C financing. MiRXES is a Singapore-headquartered biotechnology company focused on improving and saving lives with RNA-powered disease early detection tests.

This Series C financing will accelerate the company's push to deliver cancer early detection tests and preventive healthcare globally. It also brings the total amount secured by MiRXES, since its inception in 2014, to US$120 million, which marks the largest funding to date raised by a Singapore-headquartered cancer diagnostics company.

The Ogier team, led by partner Nathan Powell and managing associate Cecilia Li, provided Cayman legal advice. They worked alongside Davis Polk & Wardwell who acted for MiRXES as its Hong Kong counsel.

This Series C funding was led by CR-CP Life Science Fund, joined by global healthcare investment firm Rock Springs Capital and Singapore-based global investor EDBI and established financial institutions from the United States, Singapore, China and Hong Kong including, among others, CCBI and Keytone Ventures.

Ogier Global also provided Cayman corporate administration services to MiRXES.



No Content Set